Lead Product(s) : RAG-21
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Gains FDA Orphan Designation for RAG-21 in ALS Therapy Development
Details : RAG-21, its novel siRNA therapy targeting the FUS gene by reducing its level, for the treatment of FUS-amyotrophic lateral sclerosis
Product Name : RAG-21
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : RAG-21
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DPT0416
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DP Technology Nominates CNS-Penetrable LP-PLA2 Inhibitor For Alzheimer's Disease
Details : DPT0416 is a novel CNS penetrable small molecule targeting Lp-PLA2, being investigated for the treatment of Alzheimer's disease (AD).
Product Name : DPT0416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : DPT0416
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPU-16
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Silo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide
Details : Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.
Product Name : SPU-16
Product Type : Peptide
Upfront Cash : Undisclosed
July 08, 2024
Lead Product(s) : SPU-16
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Silo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : University Medical Center Utrecht
Deal Size : Undisclosed
Deal Type : Partnership
Ractigen Partners with University Medical Center Utrecht to Advance saRNA in Disorders
Details : This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : University Medical Center Utrecht
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : BHV-8000
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $970.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.
Product Name : BHV-8000
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
March 22, 2023
Lead Product(s) : BHV-8000
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $970.0 million
Deal Type : Licensing Agreement
Lead Product(s) : RAG-17
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RAG-17 is a therapeutic siRNA designed to target and knockdown the expression of SOD1 gene in patients with pathogenic mutations known to cause amyotrophic lateral sclerosi.
Product Name : RAG-17
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : RAG-17
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AK115
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AK115 (NGF monoclonal antibody), with the characteristics of long-term safety and non-addictive, will give priority to the evaluation of safety and efficacy in advanced cancer patients, which is expected to bring hope to opioid-resistant advanced cancer ...
Product Name : AK115
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : AK115
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Plantarum
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Psychobiotic PS128 Consumption Shows Benefits to Parkinson's Symptoms in New Clinical Study
Details : Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr. Chin-Song Lu, a renowned researcher fo...
Product Name : PS128
Product Type : Microorganism
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Lactobacillus Plantarum
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anti-TDP-43 antibody
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : AC Immune
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership focuses on developing AC Immune’s clinical antibody candidate to ensure it has high-affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.
Product Name : Anti-TDP-43 antibody
Product Type : Antibody
Upfront Cash : Undisclosed
September 11, 2020
Lead Product(s) : Anti-TDP-43 antibody
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : AC Immune
Deal Size : Undisclosed
Deal Type : Partnership